Earlier this week, Exact Sciences Chairman and CEO Kevin Conroy spoke on behalf of Exact Sciences at the J.P. Morgan Healthcare Conference. 

Conroy touched the Exact Sciences story and gave an update on the company's launch of Cologuard^®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer.

For additional investor content, including past presentations and future conference appearances, please visit our investor website.

To listen to audio of the presentation, please view the slides on the J.P. Morgan website.